Abstract
The rationale for intracoronary administration of abciximab is discussed. The data on use of intracoronary abciximab in percutaneous coronary interventions in acute coronary syndromes and STEMI are reviewed. Evaluation of the niche where intracoronary administration of abciximab may be useful and future research into the subject and relevant patents are discussed.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
